DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application

Main Article Content

Srinivas Sidgiddi
Usha Ranganathan
Anirudh Gautam

Keywords

tazarotene, pharmacokinetic, skin

Abstract

Abstract Not Available